Otsuka Tries To Halt Alkermes Ride On Abilify’s Coattails
This article was originally published in PharmAsia News
Executive Summary
FDA should not review or approve Alkermes’ NDA for aripiprazole lauroxil because it is based on only one adequate and well-controlled clinical trial, Otsuka argues.